Literature DB >> 443207

An intrinsic coagulation pathway inhibitor in a 3-year-old child.

D W Beck, R G Strauss, C T Kisker, R A Henriksen.   

Abstract

An intrinsic coagulation pathway inhibitor with acitivty against factor XI was detected in the plasma of a 3-year-old child, following a respiratory infection. The inhibitor was present transiently, but it was clinically significant and was manifiested by extensive bruises. Abnormalities of clotting and the bruising tendency disappeared simultaneously without treatment before the inhibitor could be definitively characterized. It was possibly the consequence of an adenovirus infection, as an elevated adenovirus titer was demonstrated in the patient's blood. It is possible that inhibitors of this type are more common sequelae of viral infections than realized, and perhaps a systematic effort should be made to detect them and to define their etiology and mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 443207     DOI: 10.1093/ajcp/71.4.470

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts.

Authors:  Rebecca L Sheets; Judith Stein; Robert T Bailer; Richard A Koup; Charla Andrews; Martha Nason; Bin He; Edward Koo; Holly Trotter; Chris Duffy; T Scott Manetz; Phillip Gomez
Journal:  J Immunotoxicol       Date:  2008-07       Impact factor: 3.000

2.  Transient lupus anticoagulant associated with hypoprothrombinemia and factor XII deficiency following adenovirus infection.

Authors:  U Jaeger; S Kapiotis; I Pabinger; E Puchhammer; P A Kyrle; K Lechner
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

3.  Nonclinical safety assessment of repeated administration and biodistribution of ChAd3-EBO-Z Ebola candidate vaccine.

Authors:  Camille Planty; Guillaume Chevalier; Marie-Ève Duclos; Clémentine Chalmey; Catherine Thirion-Delalande; Cécile Sobry; Ann-Muriel Steff; Eric Destexhe
Journal:  J Appl Toxicol       Date:  2020-01-21       Impact factor: 3.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.